Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market

Stock Information for Cadrenal Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cadrenal Therapeutics Inc.

Cadrenal's Quiet Expansion Play Is Starting to Get Loud
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award
Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.